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Abstract:  
Breast cancer is the most commonly diagnosed cancer in women in the United States. The 
treatment for breast cancer occurs along a protracted time period and includes many 
different disease treatment modalities. These treatments carry with them a large number of 
side effects that negatively impact function in both the short-term and long-term. It is 
necessary for rehabilitation providers to interface with patients being treated for breast 
cancer throughout the continuum of care so that interval assessments can be conducted to 
identify emerging impairments and alleviate disability. In order to achieve this, the 
rehabilitation provider must have an understanding of the clinical measurement tools best 
suited for examination and assessment of breast cancer-related impairments and disability. 
This article aims to provide a comprehensive overview of the evidence supporting the use 
of various clinical measurement tools for the breast cancer population and highlights the 
implementation of rehabilitation examination and assessment along the continuum of 
disease treatment.  
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Introduction 
Breast cancer treatment carries with it a high risk for treatment side effects that may 
negatively impact physical and psychological function. 1 Surgery, chemotherapy, 
radiation therapy, targeted agents, and hormonal therapies precipitate both immediate and 
late side effects associated with diminished function. Functional sequelae may inhibit 
return to work and performance of activities of daily living. 2 The burden of functional 
impact is significant, with over 60% of patients reporting at least one functional 
impairment during or after treatment for breast cancer. 3  
Many common treatment side effects including; pain, lymphedema, fatigue, 
peripheral neuropathies and upper quadrant impairments, such as decreased shoulder 
range of motion and strength, faulty scapular mechanics, and reduced muscle length, are 
amenable to rehabilitation interventions.1,4 Rehabilitation interventions have additional 
efficacy in early identification and treatment of many of the aforementioned common 
breast cancer-related impairments.5 Further, there is a strong evidence base to suggest 
that rehabilitation plays an integral role across the lifespan for the cancer survivor.6 
Providing interventions with demonstrable value is critically important in today’s 
health care delivery system. Value is defined not only in cost outlays for an intervention, 
but in the efficacy realized for the cost of care rendered. Rehabilitation providers must 
demonstrate that the care delivered has positively impacted the functional outcome of a 
patient. A robust movement towards value-based outcomes measurement is evident in the 
regulatory realm among both private and public payers. While there is wide acceptance 
that breast cancer treatment side effects are amenable to rehabilitation intervention, the 
mandates being put forward in health care require providers not only to objectively 
demonstrate improvement over time but to show impact on improving function related to 
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the intervention provided. This manuscript will provide the practicing rehabilitation 
provider with tools to enable evidence-based measurement of common breast cancer 
treatment-related impairments and outline the recommended outcomes tools for use in the 
breast cancer population.  
Rehabilitation across the continuum of cancer care 
Breast cancer treatment occurs over a protracted timeline with varying disease treatment 
interventions provided along that continuum; each introducing a host of potential side 
effects that may negatively impact function. Some side effects will dissipate after 
treatment is complete but some will remain and become chronic conditions. Still other 
side effects may not present until years after treatment has been completed. Many of the 
side effects that negatively impact function are amenable to rehabilitation intervention. 
Some functional impairments can be detected early, in less severe stages, when 
rehabilitation examination techniques are employed proactively. Early surveillance and 
rehabilitation intervention may prevent some side effects and may greatly reduce the 
severity of others.7 
The current model of care delivery for the patient with breast cancer frequently 
fails to address the negative functional side effects of cancer treatment until the patient 
reaches a critical threshold of disability. At this point the impairment is typically more 
severe and may even be chronic in nature. The current evidence supports rehabilitation 
examination and ongoing assessment for early detection of impairments.  Delaying 
rehabilitation frequently results in functional deficits.8,9 An ideal model of care 
proactively addresses physical function from the point of cancer diagnosis throughout the 
continuum of disease treatment, through survivorship and endures across the remaining 
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lifespan.10 (Figure 1) Such a model of care would assure comprehensive, ongoing 
functional assessment regardless of the care setting, discipline of the care provider, or 
point along the lifespan continuum. 
The prospective surveillance model as described by Stout and colleagues 
recommends a preoperative examination in all patients with breast cancer in order to 
assess pre-morbid level of function, prior physical impairments, current exercise habits 
and other co-morbidities as well as incorporating a battery of tests and measures to 
establish a baseline.7 This preoperative visit also allows for valuable education regarding 
postoperative rehabilitative exercises, advice for returning to activities during and after 
treatment as well as dialogue about known risk factors for adverse effects of the treatment 
plan. Evidence suggests that an early postoperative reassessment visit should take place 
within the first month after surgery.8,11-13 At this visit, baseline tests and measures can be 
repeated and continued education regarding exercise and return to activity can be 
provided. If functional limitations are present at this time, rehabilitation intervention can 
be initiated. If no impairments are detected, recommended ongoing surveillance should 
be continued at intervals that would correspond to specific treatments outlined in the 
patient’s care plan.7  
 At each interval follow up visit, the rehabilitation provider must be familiar with 
the changing landscape of disease treatment. For patients with early stage breast cancer, 
these punctuated time periods occur more frequently; approximately every three months 
as new treatment modalities are introduced throughout the first post-operative year. After 
the completion of active disease treatment the interval between follow up becomes less 
clear.  
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 Dietz and colleagues outline a framework that takes a comprehensive perspective 
on the role of rehabilitation for the patient with cancer.14  Dietz cites four domains of 
rehabilitation as depicted in Figure 2. The model recognizes ongoing, lifespan needs of 
the cancer survivor and identifies a role for rehabilitation throughout that spectrum.  
Considering the myriad needs of the cancer population both during and after 
treatment, the escalating number of cancer survivors and the evidence in support of 
rehabilitation as a means to improve overall functional mobility and quality of life, 
rehabilitation providers must utilize tools that validly assess and measure the impairments 
related to breast cancer treatment and further, must quantify their impact on function in 
order to demonstrate the value their interventions bring throughout the lifespan. The 
International Classification of Function enables rehabilitation providers to identify and 
measure the constructs and domains associated with disability for a given condition. A 
systematic classification system that promotes the use of valid tests and measures has 
great potential to positively demonstrate the value of rehabilitation interventions in the 
cancer population.  
International Classification of Function 
The International Classification of Functioning, Disability and Health (ICF) provides a 
construct for rehabilitation providers to identify the components of health and well-being 
of individuals. The framework enables a perspective on functioning and disability that is 
focused on the components of Body Functions and Structures and Activities and 
Participation as mechanisms to systematically classify a given health condition.15   
The ICF framework, when implemented into evaluation and assessment of the 
oncology population, has great value to informing the establishment of a plan of care and 
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enabling the practitioner to identify clinical measurement tools that strongly demonstrate 
validity based on the given health condition.16 
ICF Construct: 
ICF Functioning and Disability has two parts that are most relevant to the rehabilitation 
provider in identifying the potential disability and measuring the constructs associated 
with disability.15 These components are defined as:  
a.  Body Functions and Body Structures – These are the physiological functions of body 
systems and the anatomical parts of the body. When these components demonstrate a 
significant deviation or loss, impairment results. These components focus on the 
mechanisms of action in the body.  
b.  Activities and Participation – These components include the execution of a task or 
action by an individual or their involvement in a life situation. When these components 
demonstrate a limitation or restriction, there is difficulty functioning at both the 
individual and societal level.  
Each of the components has an extensive list of the domains of function that are 
encompassed within. These are outlined in Tables 1 and 2.  
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Table1. ICF Domains of Body Functions and Body Structures 
Body Functions Body Structures 
• Mental Functions 
• Sensory functions and pain 
• Functions of the cardiovascular, 
hematological, immunological 
and respiratory systems 
• Functions of the digestive, 
metabolic and endocrine 
systems 
• Genitourinary and reproductive 
functions 
• Neuromusculoskeletal and 
movement-related functions 
• Functions of the skin and 
related structures 
 
• Structures of the nervous 
system 
• The eye, ear and related 
structures 
• Structures involved in voice 
and speech 
• Structures of the 
cardiovascular, immunological 
and respiratory systems 
• Structures related to the 
digestive, metabolic and 
endocrine systems 
• Structures related to the 
genitourinary and reproductive 
systems 
• Structures related to movement 
• Skin and related structures 
 
Table 2. ICF Domains of Activities and Participation 
Activities and Participation 
• Learning and applying knowledge 
• General tasks and demands 
• Communication 
• Mobility 
• Self-Care 
• Domestic life 
• Interpersonal interactions and 
relationships 
• Major life areas 
• Community, social and civic life 
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Table 3. Common Breast Cancer Treatments and their impact on Activities and Participation 
Breast Cancer 
Treatments 
Body Functions and 
Structures 
Activities and 
Participation 
Clinical Measurements to Support Goals 
and Plan of Care 
Surgery:  
Breast 
• Skin and related 
structures 
• Structures related to 
movement  
• Sensory functions and 
pain 
Mobility 
Changing and maintaining 
body position 
Carrying, moving and 
handling objects 
• Functional ROM  
• Joint active and passive movement 
• Muscle length, soft tissue extensibility, 
and flexibility 
• Postural alignment and position (static 
and dynamic), including symmetry and 
deviation from midline  
• Pain, soreness, and nocioception  
• Pain in specific body parts 
• Muscle strength, power, and endurance 
during functional activities  
• Muscle tension 
Self Care 
Washing 
Dressing 
Caring for body parts 
• Functional capacity 
• Level of ability to participate in variety of 
environments 
• Level of safety in self-care activities 
• Dexterity, coordination, and agility 
• Task analysis 
• Hand function 
• Physical space and environments 
routinely encountered  
Interpersonal 
interactions and 
relationships 
Family relationships 
Intimate relationships 
• Caregiver capacity  
• Quality of life  
• Ability to assume or resume community, 
social, and civic activities with or without 
assistive technology 
Surgery:  
Lymph Node 
Dissection  
• Structures of the 
immunological system 
• Structures related to 
movement 
Mobility 
Changing and maintaining 
body position 
Carrying, moving and 
handling objects 
• Functional ROM  
• Joint active and passive movement 
• Muscle length, soft tissue extensibility, 
and flexibility 
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• Postural alignment and position (static 
and dynamic), including symmetry and 
deviation from midline  
• Pain, soreness, and nocioception  
• Muscle strength, power, and endurance 
during functional activities  
• Muscle tension 
• Lymphatic symptoms 
• Edema 
Self Care 
Washing 
Dressing 
Caring for body parts 
 
• Functional capacity 
• Level of ability to participate in variety of 
environments 
• Level of safety in self-care activities 
• Dexterity, coordination, and agility 
• Task analysis 
• Hand function 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
Chemotherapy:  
Adriamycin 
• Cardiovascular 
functions 
• Immunological functions 
• Mental Functions 
Mobility 
Walking and moving 
around 
 
• Age-appropriate activity levels  
• Balance measures  
• Dexterity, coordination, and agility   
• Falls risk factors  
• Frailty assessment to determine at-risk 
populations  
• Movement transition qualities   
• Reaction times 
• Locomotion during functional activities 
with or without the use of assistive 
technology 
• Aerobic Capacity/Endurance 
Domestic life 
Household tasks  
• Ability to gain access to home 
environments  
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Caring for household 
objects and assisting 
others 
 
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
• Functional activities of daily living 
Major life areas 
Work and employment 
 
• Cognition, including ability to process 
commands 
• Communication 
• Consciousness and orientation 
• Motivation  
• Recall, including memory and retention 
• Environmental access 
Chemotherapy:  
Cyclophosphomide 
• Reproductive functions 
• Mental functions  
• Immunological functions 
Self Care 
Looking after one’s health 
 
• Consciousness and orientation 
• Education regarding condition and self 
management of side effects 
 
Learning and applying 
knowledge 
Focusing attention 
Thinking 
Calculating 
Making decisions  
Listening 
Other purposeful sensing 
 
• Cognition, including ability to process 
commands 
• Communication 
• Consciousness and orientation 
• Motivation  
• Recall, including memory and retention 
Major life areas 
Work and employment 
 
• Cognition, including ability to process 
commands 
• Communication 
• Consciousness and orientation 
• Motivation  
• Recall, including memory and retention 
• Environmental access 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
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• Safety in performing home management 
activities 
• Functional activities of daily living 
Chemotherapy: 
Taxane (taxol, 
taxotere)  
• Structures of the 
nervous system 
• Immunological functions 
Mobility 
Changing and maintaining 
body position 
Carrying, moving and 
handling objects 
Walking and moving 
around 
• Age-appropriate activity levels  
• Balance measures  
• Dexterity, coordination, and agility   
• Falls risk factors  
• Frailty assessment to determine at-risk 
populations  
• Movement transition qualities   
• Reaction times 
 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
• Functional activities of daily living 
Radiotherapy • Skin and related 
structures 
• Structures related to 
movement 
• Immunological functions 
Mobility 
Carrying, moving and 
handling objects 
• Functional ROM  
• Joint active and passive movement 
• Muscle length, soft tissue extensibility, 
and flexibility 
• Postural alignment and position (static 
and dynamic), including symmetry and 
deviation from midline  
• Pain, soreness, and nocioception  
• Pain in specific body parts 
• Muscle strength, power, and endurance 
during functional activities  
• Muscle tension 
Self Care 
Looking after one’s health 
• Classification of wound based on 
etiology and description of depth of 
tissue destruction  
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• Positioning and postures that aggravate 
the wounded tissue or that produce or 
relieve trauma  
• Scar tissue characteristics  
• Signs of infection  
• Skin characteristics 
Major life areas 
Work and employment 
• Cognition, including ability to process 
commands 
• Communication 
• Consciousness and orientation 
• Motivation  
• Recall, including memory and retention 
• Environmental access 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
• Functional activities of daily living 
Hormonal Therapy:  
Selective Estrogen 
Receptor Modifier 
(Tamoxifen, 
Raloxifene) 
• Metabolic functions 
• Endocrine functions 
Mobility • Age-appropriate activity levels  
• Balance measures  
• Dexterity, coordination, and agility   
• Falls risk factors  
• Frailty assessment to determine at-risk 
populations  
• Movement transition qualities   
• Reaction times 
Self care 
Looking after one’s health 
• Consciousness and orientation 
• Education regarding condition and self 
management of side effects 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
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• Functional activities of daily living 
Hormonal Therapy: 
Aromatase 
Inhibitor (Arimidex, 
Aromasin) 
• Endocrine functions 
• Structures related to 
movement 
Mobility 
 
• Age-appropriate activity levels  
• Balance measures  
• Dexterity, coordination, and agility   
• Falls risk factors  
• Frailty assessment to determine at-risk 
populations  
• Movement transition qualities   
• Reaction times 
Self Care 
Looking after one’s health 
• Consciousness and orientation 
• Education regarding condition and self 
management of side effects 
• Ability to assume or resume activities 
related to self-care 
• Signs of decreased bone mineral data 
• Signs and symptoms of interrupted bony 
integrity 
Domestic life 
Household tasks 
Caring for household 
objects and assisting 
others 
• Ability to gain access to home 
environments  
• Ability to assume or resume activities 
related to home management activities  
• Safety in performing home management 
activities 
• Functional activities of daily living 
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Choosing Clinical Measurement Tools 
In order for the rehabilitation provider’s clinical examination to identify potential effects 
that may be associated with breast cancer treatment, specific tests and measures should be 
performed.  Tests and measures should be based on where the patient is along the disease 
treatment continuum, knowledge of the common side effects of treatment and 
impairments they may cause, and any presenting impairment in body function, structure 
or activity and participation limitation.  Based on Table 3, there are targeted domains that 
can be measured to support the goals and plan of care for a patient with breast cancer-
related functional loss. Tests and measures are indicated that encompass: assessment of 
upper extremity strength, joint range of motion (ROM), limb volume, pain, fatigue and 
aerobic capacity, chemotherapy induced peripheral neuropathy (CIPN), arthralgias, and 
bone density. In addition, patient self-reported measures are important clinical tools as 
they provide insight from the patient’s perspective on their level of functioning with daily 
activities and work tasks. Choosing clinical measurement tools that capture the presenting 
impairments and reflect patient self-reported function, specific to breast cancer is 
imperative.  
Clinical measurement tools are valid mechanisms by which a clinician attempts to 
provide a quantifiable assessment of an impairment or disability. The Guide to Physical 
Therapist Practice V 3.0 highlights two primary types of clinical measurement tools (Figure 
3) commonly used in physical therapist practice:17 1) Patient Self-Report measures, which 
may address the patient’s general health status, a specific condition or body region 
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impacted by a condition, 2) Objective measures, which may be impairment-based or 
performance-based.   
Figure 3. Classification of Clinical Measurement Tools 
 
 
Rehabilitation outcomes measurement is an important part of clinical practice. However, 
rehabilitation providers face many challenges in identifying and choosing optimal tools to 
objectively quantify function and to demonstrate change over time. First, there are 
numerous tools available, many with varying applicability to the breast cancer 
population. Choosing among the various tools requires knowledge of the domain that 
needs to be assessed, an understanding of valid tools available and to complete the 
assessment, and consideration for the patient’s preferences which guide the plan of care 
and anticipated outcomes of care.  
Clinical Measurement Tools
Self Report
Condition Specific
Body Region Specific
General Health Status
Objective Impairment-BasedPerformance Based
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 It is also important to consider the timing of the assessments. Measurement is 
conducted to gauge change over time and to demonstrate how this change has impacted 
functioning. Selecting tools that are sensitive to detecting change over time, specific to 
the condition being measured is the first consideration for clinicians. Timing is also a 
challenge for rehabilitation providers, as the clinical setting often does not afford 
unrestricted time to incorporate a multitude of clinical measurement tools. Therefore it is 
critical for the rehabilitation provider to identify the primary functional limitation of 
focus and precisely identify tools that closely align with measuring the limitation.  
Figures 4a and 4b provide a guide to assist the rehabilitation provider in identifying what 
type of measurement tool is most beneficial to use with consideration for the impairment 
presentation and the primary functional limitation.(ref guide to PT practice) 
The Section on Research of the American Physical Therapy Association (APTA) 
initiated work among the specialty sections to create an Evidence Database to Guide 
Effectiveness (EDGE), specifically with the intent to identify measures that have strong 
psychometric properties for use in rehabilitation.18 Useful outcome measures must 
demonstrate validity, reliability, be responsive to change, and preferably have identified 
minimal detectable change (MDC) and minimally clinically important difference (MCID) 
values.  The EDGE Taskforce of the Oncology Section of APTA has completed multiple 
systematic reviews of clinical measurement tools and classified these tools based on their 
level of supporting evidence using the EDGE rating system. Using this system, (Table 4) 
a rehabilitation provider can easily identify the clinical measurement tool with the 
strongest evidence for use in clinical practice with the breast cancer population. Tools 
rated 3 and 4 are recommended for clinical use.   
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Table 4: Oncology Section Breast Cancer EDGE Task Force Rating Scale18 
4 Highly Recommend Highly recommended; the outcome has excellent 
psychometric properties and clinical utility; the 
measure has been used in research on individuals with 
or post breast cancer. 
3 Recommend Recommended; the outcome measure has good 
psychometric properties and good clinical utility; no 
published evidence that the measure has been applied 
to research on individuals with or post breast cancer. 
2A Unable to 
Recommend at this 
time 
Unable to recommend at this time; there is insufficient 
information to support a recommendation of this 
outcome measure; the measure has been used in 
research on individuals with or post breast cancer. 
2B Unable to 
Recommend at this 
time 
Unable to recommend at this time; there is insufficient 
information to support a recommendation of this 
outcome measure; no published evidence that the 
measure has been applied to research on individuals 
with or post breast cancer. 
1 Do not Recommend Poor psychometrics &/or poor clinical utility (time, 
equipment, cost, etc.) 
 
Breast Cancer Specific Objective Tests and Measures 
Shoulder girdle muscle weakness is a commonly reported side effect from breast 
cancer treatment.8,19-23 A recent EDGE task force systematic review recommends using 
hand held dynamometry by means of a maximal voluntary isometric contraction to 
measure strength in a clinical setting.24 Tools to assess strength are outlined in Table 5. 
Research suggests assessing scapula abduction and upward rotation, scapula depression 
and adduction, glenohumeral flexion, internal rotation, scaption and horizontal adduction 
strength as these were highly correlated with upper extremity functional loss in women 
diagnosed with breast cancer.25 It is recommended that strength assessments be 
performed in a standardized manner such as published in Kendall or Hislop and 
Montgomery.26,27 
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Several studies have reported restricted shoulder motion in women who have 
received treatment for breast cancer.8,20,28-31 Table 5 reflects the recommended tools for 
measuring ROM by the EDGE task force. Passive ROM using goniometry has superior 
psychometric properties over active ROM.32 A recent study recommends assessing 
bilateral shoulder flexion, 90°ER and extension as results showed that women treated for 
breast cancer demonstrated significant limitations in these motions six months after 
breast surgery on the involved side when compared to matched healthy controls.20 It is 
advised that ROM assessments be performed in a standardized manner.33 
Limb volume is essential to measure as breast cancer-related lymphedema is a 
concern for many women diagnosed with breast cancer.34-36 The incidence of breast 
cancer-related lymphedema varies from 6% to 65% depending on the assessment tool and 
length of follow-up.37-39 Circumferential measurement, water displacement and 
bioelectrical impedance spectroscopy are highly recommended methods for assessment 
of limb volume as noted by the EDGE task force systematic review and highlighted in 
Table 6.40 The simplest of these three measures for clinical use is circumferential 
measurement. It is recommended that the individual be seated with their forearm 
pronated, and the upper extremity placed on a treatment table or measurement board in 
approximately 90° of forward flexion or abduction.41,42 Using 4cm increments proximal 
and distal to the olecranon is reliable.42 In order to convert circumferential measurement 
to a volumetric measure, the truncated Frustum formula is recommended.40,43  
Pain is one of the most commonly reported impairments after breast cancer 
treatment affecting anywhere from 16% to 73% of women treated for breast cancer.44,45 
When assessing pain in women with breast cancer, it is important to determine whether a 
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uni-dimensional or multidimensional tool is more appropriate.46 Administering the visual 
analog scale, numeric rating scale or pressure pain threshold is recommended if using a 
uni-dimensional tool is desired.  When a multidimensional tool is needed, the McGill 
Pain Questionnaire, McGill Pain Questionnaire – Short Form, Pain Disability index, Brief 
Pain Inventory, or Brief Pain Inventory – Short Form could be utilized.46 Table 7 
highlights the tools evaluated by the EDGE task force for both uni-dimensional and 
multi-dimensional pain scales.  
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of 
chemotherapy and biotherapy drugs often used to treat breast cancer.47 CIPN can lead to 
emotion distress, a decrease in functional ability, social role impairment and physical 
distress from neuropathic pain.47 Numbness and/or tingling in the distal extremities are 
typical complaints reported by patients with neuropathy. Pain may or may not be a 
component of peripheral neuropathy. A recent study conducted by Griffith and 
colleagues48 suggest administering the Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group – Neurotoxicity (FACT/COG-Ntx) and the 
shortened version of the total neuropathy score (TNS)49 
Aromatase inhibitors, a standard part of adjuvant hormone therapy for 
postmenopausal women diagnosed with breast cancer, are implicated in a myriad of 
impairments.50 A common side effect of Aromatase inhibitors are joint arthralgias, which 
negatively affect daily function.51,52 Common reported areas of arthralgias in women 
treated for breast cancer include: knee, wrist/hand, back, and ankle/foot. Currently, there 
are no well-validated measures specifically for Aromatase induced arthralgias. A recent 
study recommends asking the following questions to assess the presence of arthralgias: 
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“have you had any joint pain/stiffness in the past week?” “Did this joint pain/stiffness get 
worse after initiating therapy with an Aromatase inhibitor, and “Did you have joint 
pain/stiffness which started after initiating therapy with an Aromatase inhibitor?”52 
Several randomized clinical trials have found that a variety of breast cancer 
treatments, particularly those that induce a therapeutic premature menopause or lower 
postmenopausal estrogen concentration, are associated with bone loss.53 Women 
diagnosed with breast cancer are nearly five times more likely to experience a vertebral 
fracture in the year after their treatment when compared to healthy controls.54 Both the 
American Society of Clinical Oncology (ASCO) and the National comprehensive Cancer 
Network (NCCN) have guidelines for identification, monitoring and management of bone 
health in women diagnosed with breast cancer.55 These include bone mineral density 
screening for women treated for breast cancer who have had premature ovarian failure, 
Aromatase inhibitor use, adjuvant hormone therapy that reduces estrogen or interferes 
with estrogen action.56,57 
Breast Cancer-Specific Patient Self-Reported Measures 
As the population of women living after breast cancer continues to increase, 
overall quality of life has become an essential focus during and after initial treatment. 
There are a number of scales that assess breast cancer-specific quality of life. The 
recommended tools for use in this population are outlined in Table 8.  
The ability to use the upper extremity is essential for activities of daily living as 
well as for many occupational demands. Many women treated for breast cancer exhibit a 
loss of shoulder function in the sub-acute stages after their primary treatment.20,58,59 There 
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are a number of self-reported scales that capture the impact of pain, limited upper 
extremity mobility and strength on overall function as outlined in Table 9.  
Cancer related fatigue is a disabling symptom reported by women diagnosed with 
breast cancer to significantly impact quality of life.60-62 Similar to pain assessment, it is 
important to determine whether a uni-dimensional or multidimensional tool is better 
suited to assess fatigue in a particular patient population.  A recent systematic review 
suggests using the Brief Fatigue Inventory when planning to administer a uni-
dimensional tool or the Multidimensional Fatigue Symptom Inventory - Short Form when 
wanting to implement a multidimensional tool.63 Table 10 outlines the uni-dimensional 
and multi-dimensional assessment tools evaluated by the EDGE task force to assess 
fatigue.  
Table 9. Patient self-reported measures of upper quadrant function18  
EDGE 
Rating 
Score Clinical Measurement  4   Disability of Arm Shoulder and Hand (DASH) 4   Shoulder Pain and Disability Index (SPADI) 4   Shoulder Rating Questionnaire (SRQ) 4   Penn Shoulder Score (PSS) 3   QuickDASH 2 A 10 Questions by Wingate 2 A Modified Behavioral Rating Scale for Breast Cancer 2 A Shoulder Disability Questionnaire (SDQ) 2 A Upper Limb Disability Questionnaire (ULDQ) 2 B American Shoulder and Elbow Surgeons Score (ASES) 2 B Constant Shoulder Score 2 B Flexilevel Scale of Shoulder Function (FLEX-SF) 
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2 B Simple Shoulder Test (SST) 2 B Upper Limb Functional Index (ULFI) 2 B  Oxford Shoulder Score (OSS) 1   Functional Impairment Test- Head, and Neck/Shoulder/Arm (FIT-HaNSA) 1   Kwan’s Arm Problem Scale (KAPS) 1   Mobility Activities Measure 1   UCLA Shoulder Scale  1   Upper Extremity Functional Scale (UEFS) 
* Only those measures rated 3 or 4 are recommended for clinical practice 
Table 5. Measures of upper extremity neuromuscular and movement-related 
functions 23,24,64 
EDGE 
Rating 
Score Clinical Measurement  Functions of the joints and bones 4   Goniometry – passive range of motion 3   Goniometry – active range of motion 3  Inclinometer – active and passive range of motion 3  Assessment of “stiffness” at the GHJ 3  Pectoralis Minor muscle length assessment 3  Pectoralis minor Index, Scapular index described by Borstad 2 B Passive range of motion measurements to determine a capsular pattern of GH joint 2 B Assignment of end feel based on Cyriax continuum at the GH joint 1  Supine pectoralis minor muscle test as described by Kendall 1  Latissimus dorsi muscle length assessment test by Kendall 1  Shoulder internal rotation assessment 1  Shoulder external rotation assessment 1  Pectoralis minor muscle assessment described by Lewis 
 23 
1  Latissimus dorsi muscle length assessment described by Borstad Muscle Functions 3   Hand Grip Strength 3   Hand-held Dynamometry 2 A  Muscle Endurance 2 B Manual Muscle Test 2  B 1 Repetition Maximum 
(GHJ- Gleno-humeral Joint) 
* Only those measures rated 3 or 4 are recommended for clinical practice 
 
Table 8. Health-Related Quality of Life (HRQOL) Measures65 
EDGE 
Rating 
Score Clinical Measurement  Breast Cancer-Specific HRQOL 4   EORTC Quality of Life Questionnaire-Breast (EORTC QLQ-B23) 4   BREAST-Q 4   Functional Assessment of Cancer Therapy-Breast (FACT-B) 4   FACT-B+4 2 A  Breast Cancer Questionnaire (BCQ) 2 A Long-term Quality of Life-Breast Cancer (LTQOL-BC) 1   Brief Cancer Impact Assessment (BCIA) Cancer-Specific HRQOL 4   EORTC Quality of Life Questionnaire-Cancer (EORTC QLQ-C30) 4   Functional Assessment of Cancer Therapy-General (FACT-G)  4   Functional Living Index-Cancer (FLIC 4   Ferrans and Powers Quality of Life Index-Cancer Version (QLI-CV)  2 A  Cancer Rehabilitation Evaluation System (CARES) 
 24 
2 A Quality of Life Assessment of Cancer Patients Receiving Chemotherapy (QOL-ACD) 
* Only those measures rated 3 or 4 are recommended for clinical practice 
 
Table 6. Breast Cancer-Related Lymphedema Measurement40 
EDGE 
Rating 
Score Clinical Measurement  Clinical Outcomes Measures 4   Functional Assessment of Cancer Therapy – Breast + 4 (FACT B+4) 4   Disability of Arm, Shoulder and Hand Questionnaire (DASH) 2 A  Upper Limb Lymphedema Measure (ULL-27) 2 A Lymphoedema Functioning, Disability and Health Questionnaire (Lymph-ICF) 1  Lymph Quality of Life Measure for Limb (LYMQOL) Limb Volume Measures 4   Circumference measurement 4   Water Displacement 4   Bioelectrical Impedance Spectroscopy 2 A Tonometry 2 A Perometer 2 A Lymphedema and Breast Cancer Questionnaire (LBCQ) 2 A Visual Analogue Scale (VAS) 
* Only those measures rated 3 or 4 are recommended for clinical practice 
 
Table 7. Breast Cancer-Related Sensory Function and Pain Measures46 
EDGE 
Rating 
Score Clinical Measurement  Pain Intensity/Sensitivity 4   Visual Analog Scale 4   Numeric Pain Rating Scale 
 25 
4   Pressure Pain Threshold 2 A  Gaston – Johansson Painometer Pain Quality 4  McGill Pain Questionnaire 4  McGill Pain Questionnaire – Short Form 2 A Neuropathic Pain Scale – CIN Pain-related Disability 4  Pain Disability Index Combined Pain Measures 4  Brief Pain Inventory 4   Brief Pain Inventory – Short Form 
* Only those measures rated 3 or 4 are recommended for clinical practice 
 
Table 10. Breast Cancer-Related Fatigue Measures63 
EDGE 
Rating 
Score Clinical Measurement  One-Dimensional  4   Brief Fatigue Inventory (BFI) 3   Bi-Dimensional Fatigue Scale (BFS)/Chalder/Fatigue Questionnaire 3   Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F)  3   Visual Analog Scale 3   Wu Cancer Fatigue Scale (WCFS) 2 A Ecological Momentary Assessment of Fatigue 2 A EORTC-F 2 A Fatigue Assessment Scale (FAS) 2 A Oncology Nursing Society Fatigue Scale (ONS-FS) 2 A Rhoten Fatigue Scale (RFS) 2 A MD Anderson Symptom Inventory (MDASI) 2 B Cancer Linear Analogue Scale (CLAS)/Linear Analogue Self-Assessment Scale (LSAS) 
 26 
2 B Cancer-Related Fatigue Distress Scale (CRFDS) 2 B Edmonton Symptom Assessment System (ESAS) 2 B  Fatigue Severity Scale (FSS) 2 B NCCN Intensity Scale (NCCN-IS) 2 B NCI Common Terminology Criteria for Adverse Events 2 B Pearson-Byars Fatigue Feeling Tone Checklist (PBFFTC) 2 B Rotterdam Symptom Checklist (RSC) 2 B Symptom Distress Scale 2 B Zung Self-Rating Depression Scale Multi-Dimensional 4   FACT B 4  Multidimensional Fatigue Symptom Inventory (MFSI) 3   Diagnostic Interview for Cancer Related Fatigue (DICRF) 3   Fatigue Symptom Inventory (FSI) 3   MOS-SF36/Rand/Vitality 3   Piper Fatigue Scale Revised (PFS-R) 3  Profile of Mood States Fatigue/Vigor and Fatigue/Inertia Subscales (PMSFVS/PMSI) 2 A Cancer Fatigue Scale (CFS) 2 A Lee Fatigue Scale (formerly VAS for Fatigue) (LFS/VAS-F) 2 A Multidimensional Assessment of Fatigue/Global Fatigue Index (MAS/GFI) 2 A Multidimensional Fatigue Inventory (MFI-20/MFI) 2 A Schwartz Fatigue Scale (Revised SCFS) 2 B Fatigue Assessment Questionnaire (FAQ) 2 B Fatigue Impact Scale (FIS) 2 B Fatigue Symptom Checklist (FSC) 2 B  Fatigue Symptom Control Checklist 1  Clinical Survey for CRF (QFAS) 
 27 
1  Fatigue Item Bank (FIB) 1  Fatigue Management Barriers Questionnaire 1  Schedule of Fatigue and Anergia 1  Sphere 
* Only those measures rated 3 or 4 are recommended for clinical practice 
 
Summary 
The evaluation and treatment of patients during and after breast cancer treatment requires 
the rehabilitation provider to have knowledge about the common treatment side effect 
associated with disease treatment. An optimal approach to managing patients with breast 
cancer relies on utilizing a model of care that puts the rehabilitation provider at an 
interface with the patient from the point of diagnosis and continues throughout the 
trajectory of treatment. This model provides for interval examination and assessment of 
the patient to promote early identification of impairments and promotes reduced 
morbidity and disability long-term. There is also a need for providers to use evidence-
based practice to choose the best clinical measurement tools to assess their patient’s level 
of impairment and disability and to gauge change over time when using a prospective 
surveillance model. An understanding of the ICF and its ability to enable providers in 
better aligning their plan of care around functioning is critical.  
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